EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 323 filers reported holding EXELIXIS INC in Q3 2018. The put-call ratio across all filers is 0.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $741 | -15.4% | 32,998 | -10.6% | 0.00% | -25.0% |
Q1 2024 | $876 | -5.1% | 36,906 | -4.1% | 0.00% | 0.0% |
Q4 2023 | $923 | -60.4% | 38,481 | -36.2% | 0.00% | -33.3% |
Q3 2023 | $2,329 | +181.3% | 60,300 | +39.1% | 0.01% | +50.0% |
Q2 2023 | $828 | -1.5% | 43,347 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $841 | +21.0% | 43,347 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $695 | -99.9% | 43,347 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $680,000 | -24.6% | 43,347 | 0.0% | 0.00% | -20.0% |
Q2 2022 | $902,000 | -8.2% | 43,347 | 0.0% | 0.01% | +25.0% |
Q1 2022 | $983,000 | +17.3% | 43,347 | -5.5% | 0.00% | +33.3% |
Q4 2021 | $838,000 | -13.6% | 45,867 | 0.0% | 0.00% | -25.0% |
Q3 2021 | $970,000 | +16.0% | 45,867 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $836,000 | -19.3% | 45,867 | 0.0% | 0.00% | -20.0% |
Q1 2021 | $1,036,000 | +12.5% | 45,867 | 0.0% | 0.01% | +25.0% |
Q4 2020 | $921,000 | -17.8% | 45,867 | 0.0% | 0.00% | -33.3% |
Q3 2020 | $1,121,000 | +2.9% | 45,867 | 0.0% | 0.01% | 0.0% |
Q2 2020 | $1,089,000 | +37.8% | 45,867 | 0.0% | 0.01% | 0.0% |
Q1 2020 | $790,000 | +4.2% | 45,867 | +6.6% | 0.01% | +50.0% |
Q4 2019 | $758,000 | -0.4% | 43,014 | 0.0% | 0.00% | -20.0% |
Q3 2019 | $761,000 | -17.2% | 43,014 | 0.0% | 0.01% | -16.7% |
Q2 2019 | $919,000 | -10.3% | 43,014 | 0.0% | 0.01% | -14.3% |
Q1 2019 | $1,024,000 | -3.1% | 43,014 | -19.9% | 0.01% | -12.5% |
Q4 2018 | $1,057,000 | +10.8% | 53,716 | -0.2% | 0.01% | +33.3% |
Q3 2018 | $954,000 | -17.8% | 53,839 | -0.1% | 0.01% | -25.0% |
Q2 2018 | $1,160,000 | -3.2% | 53,894 | -0.4% | 0.01% | 0.0% |
Q1 2018 | $1,198,000 | -27.0% | 54,086 | +0.3% | 0.01% | -20.0% |
Q4 2017 | $1,640,000 | +30.0% | 53,942 | +3.5% | 0.01% | +11.1% |
Q3 2017 | $1,262,000 | -1.6% | 52,102 | +0.0% | 0.01% | 0.0% |
Q2 2017 | $1,283,000 | +37.7% | 52,101 | +21.1% | 0.01% | +28.6% |
Q1 2017 | $932,000 | +41.9% | 43,014 | -2.4% | 0.01% | +40.0% |
Q4 2016 | $657,000 | 0.0% | 44,066 | -14.3% | 0.01% | 0.0% |
Q3 2016 | $657,000 | +45.4% | 51,395 | -11.1% | 0.01% | +25.0% |
Q2 2016 | $452,000 | +95.7% | 57,837 | 0.0% | 0.00% | +100.0% |
Q1 2016 | $231,000 | -18.9% | 57,837 | +14.3% | 0.00% | 0.0% |
Q4 2015 | $285,000 | +0.4% | 50,600 | 0.0% | 0.00% | -33.3% |
Q3 2015 | $284,000 | +49.5% | 50,600 | 0.0% | 0.00% | +50.0% |
Q2 2015 | $190,000 | +46.2% | 50,600 | 0.0% | 0.00% | +100.0% |
Q1 2015 | $130,000 | +78.1% | 50,600 | 0.0% | 0.00% | 0.0% |
Q4 2014 | $73,000 | -5.2% | 50,600 | 0.0% | 0.00% | 0.0% |
Q3 2014 | $77,000 | -55.2% | 50,600 | 0.0% | 0.00% | 0.0% |
Q2 2014 | $172,000 | -3.9% | 50,600 | 0.0% | 0.00% | -50.0% |
Q1 2014 | $179,000 | -42.3% | 50,600 | 0.0% | 0.00% | -33.3% |
Q4 2013 | $310,000 | +5.4% | 50,600 | 0.0% | 0.00% | 0.0% |
Q3 2013 | $294,000 | +27.8% | 50,600 | 0.0% | 0.00% | +50.0% |
Q2 2013 | $230,000 | – | 50,600 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |